There has been much discussion in recent days on medicines pricing in the UK. The UK has some of the most robust processes in the world for ensuring value for money on medicines.
Today, 4 June, sees the unveiling of the UK’s newest life sciences asset, Health Innovation Research Alliance Northern Ireland (HIRANI) at a BIO reception in Philadelphia.
In light of the Government's announcement of an extension to article 50, ABPI commented on the position regarding stockpiling of medicines in preparation for a 'no-deal'.
Haseeb Ahmad, Managing Director, UK, Ireland & Nordics Novartis Pharmaceuticals and Country President Novartis UK has been confirmed as the new President of the ABPI.
The Government will today announce at the ABPI Conference that the most promising treatments will be fast-tracked by the new and boosted Accelerated Access Collaborative. Medicines, technologies and diagnostic tools targeting key health problems will be prioritised. The ABPI welcomes the move.
The ABPI responded to Radio 4's File on Four programme on opioids, which examined whether there are any similarities between the way in which opioid medications are being marketed by pharmaceutical companies in the US and the UK.
The Migration Advisory Committee has published their full review of the shortage occupation list (SOL) and recommended that a number of fields be added to the list.
Today (23 May), the ABPI and the AHSN Network publish a new guide to cross-sector working between NHS Sustainable Transformation Partnerships (STPs), Integrated Care Systems (ICSs) and industry. The guide sets out governance and process recommendations to make collaboration more straightforward.
Life sciences is among a select group of highly innovative industries linked to science and tech which could be responsible for a new wave of growth worth an extra £14 billion a year to the UK economy by 2025.
Health Secretary Matt Hancock has announced that all opioid medicines in the UK will carry prominent warnings on the labels saying they can cause addiction.